Sung Sook Lee

Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring <i>ROS1</i> Rearrangement

Sun Min Lim, Hye Ryun Kim, Jong-Seok Lee et al. · Journal of Clinical Oncology · 2017 · 297 citations · Full text

Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report

James Chih‐Hsin Yang, Frances A. Shepherd, Dong‐Wan Kim et al. · Journal of Thoracic Oncology · 2019 · 201 citations · Full text

Significant Association of Oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients

Keun‐Wook Lee, Sung Sook Lee, Sang-Bae Kim et al. · Clinical Cancer Research · 2014 · 158 citations · Full text

Brain metastases in breast cancer: prognostic factors and management

Sung Sook Lee, Jin‐Hee Ahn, Min Kyoung Kim et al. · Breast Cancer Research and Treatment · 2007 · 156 citations

Neuro-oncology, Breast Oncology, Brain Metastases +5

Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study

Myung‐Ju Ahn, Ji‐Youn Han, Ki Hyeong Lee et al. · The Lancet Oncology · 2019 · 132 citations

Dose Expansion Parts, Dose Escalation, Medicine +8